TABLE 2.
Comparison of ultrasound adherence based on patient, tumor, and follow-up characteristicsa
| Characteristic | US non-adherence (n = 72) n (%) |
US adherence (n = 37) n (%) |
p Value |
|---|---|---|---|
|
| |||
| Age: years (IQR) | 58.5 (46.5–68) | 59 (45–68) | 0.77 |
| Male gender | 43 (60) | 18 (49) | 0.27 |
| Travel distance: miles (IQR) | 79.2 (34–114.1) | 64.8 (28.5–104) | 0.44 |
| Tumor location | 9(12) | 5 (14) | 0.11 |
| Head or neck | 25 (35) | 6(16) | |
| Upper extremity | 29 (40) | 16 (43) | |
| Trunk | 9(12) | 10 (27) | |
| Lower extremity | |||
| Breslow depth: mm (IQR) | 2.5 (1.4–4.4) | 1.9 (1–4.3) | 0.24 |
| No. of positive SLNs (IQR) | 1 (1–2) | 1 (1–1) | 0.04 |
| Stage (AJCC 8th ed) | 0 (0) | 1 (3) | 0.36 |
| 3A | 39 (54) | 20 (54) | |
| 3B | 32 (44) | 14 (38) | |
| 3C | 1 (1) | 1 (3) | |
| 3D | 0 (0) | 1 (3) | |
| Unavailable | |||
| Received adjuvant systemic therapy | 44 (61) | 18 (49) | 0.07 |
| If lost to follow-up, did patient have planned surveillance with outside medical oncologist? | 33 (67) | 1 (9) | 0.22 |
| 6(12) | 5 (45) | ||
| Yes | 10 (20) | 5 (45) | |
| No | |||
| Unknown | |||
US Ultrasound, IQR Interquartile range, SLN Sentinel lymph node, AJCC American Joint Committee on Cancer
a
Data are presented as median (IQR) for continuous measures, and n (%) for categorical measures